Premium
Letter: lessons from the ‘real‐world’ entecavir therapy in chronic hepatitis B patients
Author(s) -
Chang M.L.,
Liaw Y.F.
Publication year - 2016
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.13553
Subject(s) - medicine , discontinuation , declaration , entecavir , intensive care medicine , safer , hbsag , chronic hepatitis , immunology , hepatitis b virus , virus , lamivudine , computer security , political science , computer science , law